Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-25
2011-11-29
Westerberg, Nissa (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S277000, C514S345000, C514S351000
Reexamination Certificate
active
08067444
ABSTRACT:
The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
REFERENCES:
patent: 5254572 (1993-10-01), Serfontein
patent: 5288716 (1994-02-01), Speck
patent: 5985857 (1999-11-01), Hudson et al.
patent: 6228858 (2001-05-01), Hudson et al.
patent: 6436969 (2002-08-01), Khalifah et al.
patent: 6472400 (2002-10-01), Hudson et al.
patent: 6472411 (2002-10-01), Hudson et al.
patent: 6489345 (2002-12-01), Sethi et al.
patent: 6521645 (2003-02-01), Voziyan et al.
patent: 6716858 (2004-04-01), Khalifah et al.
patent: 6730686 (2004-05-01), Baynes et al.
patent: 6740668 (2004-05-01), Baynes et al.
patent: 6750209 (2004-06-01), Hudson et al.
patent: 6894058 (2005-05-01), Cameron et al.
patent: 2002/0128295 (2002-09-01), Baynes
patent: 2003/0013746 (2003-01-01), Hudson et al.
patent: 2003/0181492 (2003-09-01), Baynes et al.
patent: 2004/0220090 (2004-11-01), Hudson et al.
patent: 2376029 (2001-01-01), None
patent: 01/13900 (2001-03-01), None
Jardine et al., Journal of Cardiovascular Pharmacology, 34 (Suppl. 1), S31-34, 1999.
Rahn et al., Journal of Hypertension, 17(3), 309-317, 1999.
Wassenberg JJ, Fox JW, Degenhardt TP, Szabo JR, Khalifah RG. Pyridoxamine (Pyridorin™) reduces urinary TGF-b1 in phase 2 clinical studies (PYR-205/207) on type 1 and type 2 diabetic patients with overt nephropathy. J Am Soc Nephrol. 15:729A, 2004.
Bell DH, Degenhardt TP, Szabo JR, Khalifah RG Schotzinger RJ. Investigation of the safety and efficacy of pyridoxamine (Pyridorin™) in patients with diabetic nephropathy (PYR-206). Diabetes 53 Suppl 2:A119, 2004.
McGill JB, Degenhardt TP, Szabo JR, Khalifah RG, Schotzinger RJ. A phase 2 clinical investigation of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR-205/207). Diabetes 53 Suppl 2:A138, 2004.
Distiller LA, Malik RA, Degenhardt TP, Szabo JR, Khalifah RG, Schotzinger RJ. Clinical investigation of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt diabetic nephropathy (PYR-205/207). Diabetol 47 Suppl 1:A89, 2004.
Cameron NE, Cotter MA, Chen Y, Khalifah R.G. Correction of neurovascular dysfunction in diabetic rats by the novel non-nucleophilic advanced glycation inhibitor BST-4997. Diabetes 53 Suppl 2:A209, 2004.
Khalifah RG, Chen Y, Price D, Booth A. Structure-activity relations of Pyridorin™ and related novel compounds in relation to their mechanism of AGE inhibition. Diabetes 52 Suppl 1:A187, 2003.
Khalifah RG, Chen Y, Price D, Booth A. Structure-activity relations of Pyridorin™ and related novel compounds in relation to their mechanism of AGE inhibition. Diabetol 46 Suppl 2:A406, 2003.
Wassenberg JJ, Knight, ST, Fox JW, Degenhardt TP, Szabo JR, Khalifah RG. The AGE inhibitor pyridoxamine (Pyridorin™) reduces urinary TGF-b1 in diabetic patients with overt nephropathy. J Am Soc Nephrol. 14:395A, 2003.
Degenhardt TP, Khalifah RG, Klaich GM, Schotzinger RJ. Pharmacokinetics, tolerability and biological activity of oral Pyridorin™, a novel AGE inhibitor, in patients with type 1 diabetes and nephropathy. J Am Soc Nephrol 13:652A, 2002.
Khalifah RG, Chen Y, Price DL, Booth AA. Mechanism of action of Pyridorin™ (pyridoxamine), a novel therapeutic for diabetic complications. J Am Soc Nephrol 13:535A, 2002.
Khalifah RG, Chen Y, Price DL, Booth AA. Mechanism of inhibition of advanced glycation end products by Pyridorin™, a novel therapeutic for diabetic complications. Diabetol 45 Suppl 2:A393, 2002.
Degenhardt TP, Khalifah RG, Schotzinger RJ. Human pharmacokinetics and metabolism of oral Pyridorin™, a novel therapeutic for diabetic nephropathy. Diabetol 45 Suppl 2:A366, 2002.
Degenhardt TP, Khalifah RG, Schotzinger RJ. Pharmacokinetics of oral Pyridorin™, a novel AGE inhibitor, in human subjects. Diabetes 51 Suppl 2:A185, 2002.
Murphy, P.A., “Alternative Therapies for Nausea and Vomiting of Pregnancy”, Obstetrics & Gynecology, Jan. 1998, 91(1):149-155.
Degenhardt, et al. “Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat”, Kidney International, vol. 61, (2002), pp. 939-950.
Michailova, et al., (1992), Clinical Pharmacology Therapy and Toxicology, “Inhibitory effect of vitamin B6 on nonenzymatic glycation of albumin and hemoglobin”, pp. 547-548.
Khatami, et al., (1988), Life Sciences, “Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation”, vol. 43, pp. 1725-1731.
Robert Schotzinger
Thorsten Degenhardt
Wesley Fox J.
McDonnell Boehnen & Hulbert & Berghoff LLP
NephroGenex, Inc.
Westerberg Nissa
LandOfFree
Pyridoxamine for the treatment of diabetic intermediaries... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridoxamine for the treatment of diabetic intermediaries..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridoxamine for the treatment of diabetic intermediaries... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4264385